Researchers found that the global morbidity gap increased from 8.8 to 10.7 years from 1990 to 2023, a 21.9% increase. HealthDay News — The global morbidity gap increased from 1990 to 2023, according ...
Supported by four phase 3 clinical trials, Simtriyo offers a novel triple-reuptake inhibition mechanism for managing core ADHD symptoms across pediatric and adult populations.
The votes are nonbinding, but they amount to a rebuke of the FDA’s own scientists who said the drugs have not been studied enough to know whether they are safe or effective.
Emergency presentation (EP) for cancer diagnosis is common among older US adults and predicts persistently elevated mortality, according to a study published online July 14 in the Journal of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results